Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic pathology in
industrialized countries, affecting about 25% of the general population. NAFLD is a benign …

Hypoglycemic medications that could be co-administered with prebiotics and functional
foods can potentially reduce the burden of metabolic diseases such as Type 2 Diabetes …

Scope Glucagon‐like peptide‐1 (GLP‐1) deficiency occurs in obesity‐related pathologies
due to defects in the intestinal lumen. And expanding the L‐cell population has emerged as …

Background Incretin impairment refers to L-cell-derived glucagon-like peptide-1 (GLP-1)
deficiency, commonly observed in patients with type 2 diabetes mellitus (T2DM). Promoting …

Dietary nutrients regulate intestinal homeostasis through a variety of complex mechanisms,
to affect the host health. Nowadays, various models have been used to investigate the …

High dietary glucose consumption and hyperglycemia can result in chronic complications.
Several studies suggest that high glucose (HG) induces dysfunction of the intestinal barrier …

Type 2 diabetes and renal damage are strictly linked. The progressive increase in T2D
incidence has stimulated the interest in novel biomarkers to improve the diagnostic …

Aims Glucagon-like peptide 1 (GLP-1) is produced by the L subtype of enteroendocrine cells
(EECs). Patients with type 2 diabetes (T2D) exhibit reduced incretin effect, but the …

Many treatments have been used for glucose metabolism diseases such as type 2 diabetes,
and all of those treatments have several advantages as well as limitations. This review …

Diabetic kidney disease (DKD) is a complication that strongly increases the risk of end-stage
kidney disease and cardiovascular events. The identification of novel, highly sensitive, and …